R21/Matrix-M - two vial formulation for malaria

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Dec 2021: Trial registered, NCT05155579
  2. 14 May 2022: Trial started, NCT05155579

The trials

NCT05155579: Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

State
Completed
Phase
Phase 1
People
594 taking part
Started
14 May 2022
Primary completion
27 May 2025
Arms
Groups 1a, 2a and 3a
Results
None posted
  1. 13 Dec 2021: Trial registered
  2. 14 May 2022: Trial started
  3. 27 May 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.